Vita 34 AG
XETRA:V3V
Vita 34 AG
XETRA:V3V
Price:
4.76 EUR
Updated:
May 20, 2024
Vita 34 AG
Note Receivable
|
Vita 34 AG
Note Receivable Peer Comparison
Comparables:
F
FME
FRE
E
1846
SYAB
Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vita 34 AG
XETRA:V3V
|
Note Receivable
€9.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
54%
|
CAGR 10-Years
23%
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Synlab AG
XETRA:SYAB
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vita 34 AG's Note Receivable?
Note Receivable
9.4m
EUR
9.4m
EUR
Based on the financial report for Dec 31, 2023, Vita 34 AG's Note Receivable amounts to 9.4m EUR.
What is Vita 34 AG's Note Receivable growth rate?
Note Receivable CAGR 10Y
23%
23%
Over the last year, the Note Receivable growth was 156%.
You don't have any saved screeners yet
